Your shopping cart is currently empty

PDGFR-IN-1 is an orally active, highly efficient platelet-derived growth factor receptor (PDGFR) inhibitor with potent antitumor activity. It inhibits PDGFRα and PDGFRβ and can be used in solid tumor research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $189 | - | In Stock | |
| 5 mg | $479 | - | In Stock | |
| 10 mg | $728 | - | In Stock | |
| 25 mg | $1,280 | - | In Stock | |
| 50 mg | $1,850 | - | In Stock | |
| 100 mg | $2,500 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $483 | - | In Stock |
| Description | PDGFR-IN-1 is an orally active, highly efficient platelet-derived growth factor receptor (PDGFR) inhibitor with potent antitumor activity. It inhibits PDGFRα and PDGFRβ and can be used in solid tumor research. |
| Targets&IC50 | PDGFRα:2.4 nM, PDGFRβ:0.9 nM |
| In vitro | PDGFR-IN-1 is a potent inhibitor of PDGFR (platelet-derived growth factor receptor) with IC50 of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 showed the highest antiproliferative activity against human osteosarcoma cancer cell lines with abnormal PDGFRα and/or PDGFRβ activation (MG63, U2OS, MNNG/HOS, and SAOS-2). The IC50 values were 0.44, 0.42, 1.03 and 0.37 μM, respectively. PDGFR-IN-1 (0.1, 0.2, and 0.4 μM) inhibited α-tubulin expression IN MNNG/HOS and MG63 cells in a dose-dependent manner, thereby inhibiting cancer cell formation. PDGFR-IN-1 inhibits PDGFRβ phosphorylation and downstream signal transduction (p-STAT3, p-AKT, and p-ERK) IN MNNG/HOS cells. PDGFR-IN-1 significantly inhibits the migration and invasion of osteosarcoma cancer cells by down-regulating the expression of FAK and its distribution on the cell front. [1] |
| In vivo | Orally administered PDGFR-IN-1 (40, 80 mg/kg/ day for 10 days), the mice showed good resistance. IN a MNNG/HOS xenograft mouse model, PDGFR-IN-1 (30 mg/kg for 14 days) treatment significantly inhibited tumor growth. [1] |
| Molecular Weight | 458.56 |
| Formula | C25H30N8O |
| Cas No. | 2644673-07-2 |
| Smiles | N1=CC=2C=CC(=CC2N1)NC3=NC(=NC=C3C)NC4=CC=C(C(OC)=C4)N5CCN(CC)CC5 |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (174.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.9 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.